We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Bluebird Bio has been singing the praises of two new therapies at the annual American Society of Hematology, but although the data look solid so far, investors don’t seem to be fully on board with the program.......